LeMaitre Vascular Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw 11% sales growth, 42% EPS growth, and record results across all major product lines and geographies. Artegraft led with 36% global growth, and guidance was raised for revenue, margins, and EPS for the full year. Cash flow and capital position remain strong.
Fiscal Year 2025
-
Q4 2025 saw 16% sales growth, 71.7% gross margin, and 47% operating income growth, with strong international expansion and product launches. 2026 guidance projects 12% sales growth, 21% adjusted operating income growth, and continued margin expansion.
-
Q3 delivered 12% organic growth, record margins, and strong cash flow, with biologics and international launches outperforming expectations. Full-year guidance was raised for revenue, operating income, and EPS, despite headwinds from a catheter recall and FX.
-
Q2 2025 saw 15% sales growth, 70% gross margin, and 16% EPS growth, with strong performance in catheters, grafts, and international markets. Full-year guidance was raised across all key metrics, and new product launches and regulatory progress are expected to drive continued growth.
-
Q1 2025 saw 13% organic sales growth, record results across all product lines, and a raised 2025 sales guidance to $245 million. Gross margin improved to 69.2%, and the company expanded its sales force and direct international presence, with Artegraft's European launch imminent.
Fiscal Year 2024
-
Q4 2024 saw 14% sales growth, 26% higher operating income, and 30% EPS growth, driven by strong product and geographic performance. 2025 guidance calls for 10% organic sales growth, 69.7% gross margin, and continued sales force expansion, with new product launches and regulatory milestones expected.
-
Q3 2024 delivered 16% sales growth and 49% EPS growth, driven by strong pricing, operational execution, and expansion in direct sales channels. Gross margin improved to 67.8%, with raised Q4 guidance and continued regulatory progress, while disciplined capital allocation supports future growth.
-
Q2 2024 delivered 12% organic sales growth and 44% EPS growth, with strong performance across product lines and regions. Gross margin rose to 68.9%, and full-year guidance was raised for both sales and EPS. Regulatory progress and sales force expansion support continued momentum.